Roche Pharmaceutical Development and Sales Overview

Tecentriq Global sales CHFbn CER growth +10% Regional sales CER growth US +9% 3.2 2.8 Europe +19% 2.4 2.0 1.6 1.2 0.8 Japan -5% International +16% 0.4 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 2,692m • • US: Growth driven by first-in-class launches in adjuvant PDL1+ NSCLC, in 1L HCC and 1L SCLC EU: Growth driven by first-in-class launches in adjuvant PDL1+ NSCLC, in 1L HCC and 1L SCLC ● Japan: 11% price cut in Q2 2021 CER-Constant Exchange Rates Roche 154

View entire presentation